

GASTROENTEROLOGY

PAPER-II

GASTRO/J/18/10/II

Time: 3 hours

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space
- Answer all the parts of a single question together.
- Start the question to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

- | | | |
|----|---|-----|
| 1. | a) Define various diagnostic criteria for acute on chronic liver failure. | 4+6 |
| | b) Management of a patient with acute on chronic liver failure | |
| 2. | a) Classify and enumerate various cystic lesions of the pancreas. | 4+6 |
| | b) Investigational and management approach to a patient with Intraductal papillary mucinous neoplasm (IPMN) | |
| 3. | a) Definition, causes and approach to a case of indeterminate biliary stricture | 5+5 |
| | b) Dominant stricture in primary sclerosing cholangitis | |
| 4. | a) What are causes of dyspnoea in patients with cirrhosis of the liver? | 2+8 |
| | b) Pathophysiology and management of Hepatopulmonary syndrome. | |
| 5. | a) Pathophysiology of pain in chronic pancreatitis | 5+5 |
| | b) Discuss the various modalities of treatment for patients with chronic pancreatitis for pain relief | |
| 6. | a) Enterohepatic circulation of bile acids | 5+5 |
| | b) Brown pigment gallstones: Pathophysiology and management | |
| 7. | a) Management of chronic hepatitis C virus in a patient with chronic renal failure who is a prospective kidney transplant candidate. | 5+5 |
| | b) Write a short note (with a diagram) on the site of action of different classes of direct acting antiviral drugs against hepatitis C virus. | |
| 8. | a) Non-invasive assessment for liver fibrosis and how does it help in clinical management of patients. | 5+5 |
| | b) Newer drugs with their mechanism of action for treating non-alcoholic fatty liver disease | |

P.T.O.

- *****